Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus YASMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus YASMIN.
BALZIVA-28 vs YASMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins, inhibiting ovulation. Drospirenone has antimineralocorticoid activity, reducing water retention, and antiandrogenic activity.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
One tablet (ethinyl estradiol 0.03 mg / drospirenone 3 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
Terminal elimination half-life is approximately 30 hours for drospirenone; steady-state concentration is achieved after 10 days of daily dosing.
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Approximately 40% renal and 60% fecal after oral administration; metabolites are excreted as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive